Victor Hernandez-Olmos, Jan Heering, Niklas Ildefeld, Johanna H. M. Ehrler, Alexander Kaps, Rinusha Rajkumar, Beatrice Marinescu, Astrid Kaiser, Igor Macinkovic, Mohammed A. F. Elewa, Mohamad Wessam Alnouri, Lewis Elson, Manfred Schubert-Zsilavecz, Wiebke Kallenborn-Gerhardt, Achim Schmidtko, Susanne Müller, Stefan Offermanns, Dieter Steinhilber, Andreas Weigert, Ewgenij Proschak
{"title":"支架跳跃激活BLT2化学探针的鉴定","authors":"Victor Hernandez-Olmos, Jan Heering, Niklas Ildefeld, Johanna H. M. Ehrler, Alexander Kaps, Rinusha Rajkumar, Beatrice Marinescu, Astrid Kaiser, Igor Macinkovic, Mohammed A. F. Elewa, Mohamad Wessam Alnouri, Lewis Elson, Manfred Schubert-Zsilavecz, Wiebke Kallenborn-Gerhardt, Achim Schmidtko, Susanne Müller, Stefan Offermanns, Dieter Steinhilber, Andreas Weigert, Ewgenij Proschak","doi":"10.1021/acs.jmedchem.4c01617","DOIUrl":null,"url":null,"abstract":"The leukotriene B4 receptor 2 (BLT2) is a G-protein coupled receptor, which is endogenously activated by 12(<i>S</i>)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT). BLT2 is gaining attention as a potential therapeutic target involved in various pathologies including diabetic wound healing, ophthalmic diseases, and colitis. However, validation of BLT2 as drug target requires chemical probes and pharmacological tools which will allow for application in vivo. In this work, we present the discovery of a novel chemical probe <b>T-10430</b> for BLT2 agonism following a scaffold-hopping approach. <b>T-10430</b> exhibits high potency, good selectivity profile, promising physicochemical and PK properties and can potentially serve as orally applicable pharmacological tool for validation of BLT2 as drug target. Using <b>T-10430</b>, we demonstrate the beneficial effect of BLT2 activation in mouse model of psoriasis.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"26 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification of a Chemical Probe for BLT2 Activation by Scaffold Hopping\",\"authors\":\"Victor Hernandez-Olmos, Jan Heering, Niklas Ildefeld, Johanna H. M. Ehrler, Alexander Kaps, Rinusha Rajkumar, Beatrice Marinescu, Astrid Kaiser, Igor Macinkovic, Mohammed A. F. Elewa, Mohamad Wessam Alnouri, Lewis Elson, Manfred Schubert-Zsilavecz, Wiebke Kallenborn-Gerhardt, Achim Schmidtko, Susanne Müller, Stefan Offermanns, Dieter Steinhilber, Andreas Weigert, Ewgenij Proschak\",\"doi\":\"10.1021/acs.jmedchem.4c01617\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The leukotriene B4 receptor 2 (BLT2) is a G-protein coupled receptor, which is endogenously activated by 12(<i>S</i>)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT). BLT2 is gaining attention as a potential therapeutic target involved in various pathologies including diabetic wound healing, ophthalmic diseases, and colitis. However, validation of BLT2 as drug target requires chemical probes and pharmacological tools which will allow for application in vivo. In this work, we present the discovery of a novel chemical probe <b>T-10430</b> for BLT2 agonism following a scaffold-hopping approach. <b>T-10430</b> exhibits high potency, good selectivity profile, promising physicochemical and PK properties and can potentially serve as orally applicable pharmacological tool for validation of BLT2 as drug target. Using <b>T-10430</b>, we demonstrate the beneficial effect of BLT2 activation in mouse model of psoriasis.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.4c01617\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c01617","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
白三烯B4受体2(BLT2)是一种g蛋白偶联受体,由12(S)-羟基庚十四- 5z,8E, 10e -三烯酸(12- hht)内源性激活。作为一种潜在的治疗靶点,BLT2在包括糖尿病伤口愈合、眼科疾病和结肠炎在内的各种病理中都受到关注。然而,BLT2作为药物靶点的验证需要化学探针和药理学工具,以便在体内应用。在这项工作中,我们提出了一种新的化学探针T-10430在支架跳跃方法后用于BLT2激动作用。T-10430具有高效、良好的选择性、良好的物理化学和PK特性,有可能作为口服药理工具验证BLT2作为药物靶点。利用T-10430,我们证实了激活BLT2对银屑病小鼠模型的有益作用。
Identification of a Chemical Probe for BLT2 Activation by Scaffold Hopping
The leukotriene B4 receptor 2 (BLT2) is a G-protein coupled receptor, which is endogenously activated by 12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT). BLT2 is gaining attention as a potential therapeutic target involved in various pathologies including diabetic wound healing, ophthalmic diseases, and colitis. However, validation of BLT2 as drug target requires chemical probes and pharmacological tools which will allow for application in vivo. In this work, we present the discovery of a novel chemical probe T-10430 for BLT2 agonism following a scaffold-hopping approach. T-10430 exhibits high potency, good selectivity profile, promising physicochemical and PK properties and can potentially serve as orally applicable pharmacological tool for validation of BLT2 as drug target. Using T-10430, we demonstrate the beneficial effect of BLT2 activation in mouse model of psoriasis.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.